About Aastrom

Founded in 1989 and with headquarters in Ann Arbor, Michigan, Aastrom Biosciences is dedicated to the development of treatments for critical cardiovascular diseases. Aastrom is currently evaluating its autologous cellular therapies in late-stage U.S. clinical trials in the treatment of critical limb ischemia (CLI) and dilated cardiomyopathy (DCM). These critical diseases are associated with significant morbidity and mortality and very limited treatment options.

To fulfill Aastrom’s mission of helping people with CLI and DCM realize the promise of patient-specific therapy, we hold fast to our values, always using rigorous scientific methods to test hypotheses and evaluate our products’ potential. Personal integrity and accountability to our stakeholders are the foundations of our work, and we seek to practice transparency and openness in our dealings with each other, our patients, and our investors.

Read more about our mission and values or about partnering with Aastrom, or contact us for additional information.